



HAL
open science

Bone sarcomas in the immunotherapy era

Marie-Françoise Heymann, Kristina K Schiavone, Dominique Heymann

► **To cite this version:**

Marie-Françoise Heymann, Kristina K Schiavone, Dominique Heymann. Bone sarcomas in the immunotherapy era. *British Journal of Pharmacology*, 2020, Epub ahead of print. 10.1111/bph.14999 . inserm-02458301

HAL Id: inserm-02458301

<https://inserm.hal.science/inserm-02458301>

Submitted on 28 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Bone sarcomas in the immunotherapy era

Marie-Françoise Heymann^{1,2,3}, Kristina Schiavone^{1,2}, Dominique Heymann^{1,2,3,*}

¹ Université de Nantes, INSERM, Institut de Cancérologie de l'Ouest, CRCINA, 44805 Saint Herblain cedex, France.

² Institut de Cancérologie de l'Ouest, "Tumor Heterogeneity and Precision Medicine", Blvd Jacques Monod, 44805 Saint Herblain, France.

³ INSERM, European Associated Laboratory "Sarcoma Research Unit", Department of Oncology and Metabolism, Medical School, University of Sheffield, United Kingdom.

Running title Immunotherapies in bone sarcomas

***Correspondence**

Prof. D. Heymann

E-mail: dominique.heyman@univ-nantes

Conflict of interest: None

Keywords: immunotherapy; immune tolerance; immune reprogramming; checkpoint inhibitors; osteosarcoma; chondrosarcoma; Ewing sarcoma

ABSTRACT

Bone sarcomas are primary bone tumors which occur mainly in children and adolescents, in the form of osteosarcoma and Ewing sarcoma, and in people in their 40s, in the form of chondrosarcoma. The last four decades have been characterized by the development of therapeutic approaches based on drug combinations, but with no real improvement in overall survival. Recent progress made in the field of oncoimmunology has made it possible to better understand the crucial role played by immune infiltrate in the oncologic process and has led to recent clinical trials with a common aim: reprogramming the immune system in order to facilitate cancer cell recognition. Similarly, immune infiltrates of bone sarcomas have been characterized and the first molecular profiling identified potential immune therapeutic targets, which have been used for designing ongoing clinical trials. Unfortunately, the objective clinical responses in clinical trials remain anecdotal but highlight the necessity to better characterize tumor microenvironment of bone sarcoma to unlock the immunotherapeutic response especially in their pediatric forms. Bone sarcomas have thus entered the immunotherapy era. The present review gives a brief overview of the most recent developments in immunotherapies in bone sarcomas.

Abbreviations:

CAR: Chimeric Antigen Receptor; CART T: CAR engineered T-lymphocytes; CTC: Circulating Tumor Cell; CTLA-4: Cytotoxic T-Lymphocyte Associated Protein 4 positive; IL: Interleukin; L-MTP-PE: Liposomal-Muramyl TriPeptide- Phosphatidyl Ethanolamine; MAGE: Melanoma-Associated antiGEN; NK: Natural Killer; NKGD2: Natural Killer Group 2 member D; NY-ESO1: New York ESophageal squamous cell carcinoma 1; PD-L1: Programmed Death-Ligand 1; TAM: Tumor Associated Macrophages; TIL: Tumor Infiltrating Lymphocytes; TIM-3: T cell Immunoglobulin and Mucin-domain containing-3

Introduction

With less than 0.2% of malignant tumors, bone sarcomas are considered to be orphan tumors. These sporadic malignancies are of mesenchymal origin and result from oncogenic and epigenetic events occurring during the differentiation process of mesenchymal stem cells, as well as a permissive microenvironment [Brown *et al.*, 2018]. Bone sarcomas affect preferentially children and young adults, but are not restricted to the young as they can also affect older patients, with incidence depending on histological subtypes [Brown *et al.*, 2018]. The three main common forms of bone sarcoma are osteosarcoma (56%), Ewing sarcoma (34%) and chondrosarcoma (6%), the first two subtypes affecting principally young patients, with a peak of incidence around 18 and 15 years old respectively, while the latter is more common in adults, with a peak of incidence in people in their 40s. Despite their rare incidence, bone sarcomas are characterized by a high mortality rate (e.g. development of lung metastases in osteosarcoma and Ewing sarcoma) and/or morbidity rate (e.g. high risk of local recurrence in chondrosarcoma). Extensive surgical resection with adequate margins in healthy tissues is the central therapeutic procedure for these three tumor entities, combined with adjuvant and neo-adjuvant chemotherapy composed of a cocktail of three drugs (from doxorubicin, cisplatin, methotrexate and ifosfamide) for osteosarcoma, and four drugs for Ewing sarcoma (vincristine, ifosfamide, doxorubicin and etoposide) [Whelan and Davis 2018]. High-grade conventional chondrosarcomas require wide, en-bloc local excision with negative margins and chemotherapy can be proposed for unresectable tumors or recurrent or metastatic disease [Polychronidou *et al.*, 2017; Whelan and Davis 2018]. Unfortunately, despite the aggressive therapeutic arsenal, overall survival, which is around 65% at 5 years for localized osteosarcoma and Ewing sarcoma and 20-30% at 5 years for patients with metastases, and 50-60% at 10 years for chondrosarcoma according to the histological subtype

has not improved in the last four decades and has led to the development of new therapeutic strategies [Heymann *et al.*, 2016].

Immune surveillance is a complex biological process that combines the recognition of tumor cells and by specific effector cells tightly controlled by regulatory immune cells. In turn, tumor cells can secrete soluble factors (e.g. cytokines) to downmodulate the immune surface makers and dampen the immune system. The concept of immunological surveillance was first proposed by Burnet F.M. 50 years ago [Burnet, 1970] and was further refined into the term “cancer immunoediting” [Dunn *et al.*, 2004]. The dual function of immune system in the control of tumor surveillance includes three stages. The first named “elimination” is characterized by the tumor infiltration by innate and adaptive immune cells which eradicate sensitive cancer cells. The second stage is defined by a dynamic “equilibrium” between surviving neoplastic cells and immune infiltrate which exerts a dynamic selective pressure on cancer cells. This selective pressure induces the emergence of cancer-cell subpopulations with specific properties of immune escape or/and immunosuppression and expansion capacity in immunocompetent microenvironment. The immune “escape” is consequently the third stage of the immunoediting is considered to be a hallmark of cancer. The immune system plays then a dual function by slowing down the tumor progression in a first intention and by facilitating the tumor growth after the modeling phase of immunogenic phenotype of tumor cells. Of the potential new targets, the immune environment has received considerable attention and to make an immunotolerant environment in immunocompetent territory is the challenge of immunotherapy for reinducing an antitumoral response. The local immune tolerance results for establishing a permissive microenvironment that is beneficial for cancer cells, have led to the development of new immune-based therapeutic approaches (Figure 1A-C).

The present review gives a brief overview of the most recent developments in immunotherapies in bone sarcomas focusing on the current state of adoptive cell therapy, immune checkpoint inhibitors or vaccine and drug approaches. The manuscript will describe the disappointing results of the first clinical trials and will underline the promising track proposed for reeducating the immune system into immunocompetent therapeutic tool.

Historical observation leading to ongoing clinical development

Even immunotherapeutic approaches are still in their early stages in sarcomas, the first evidence of functional immune intervention in sarcomas was reported by Coley, more than 120 years ago. Coley observed complete remission in 10% of patients after inoculation of heat-inactivated *Streptococcus pyogenes* and *Serratia marcescens*, known as Coley's toxin. Similar observations were made by Jeys *et al.* (2007) in osteosarcoma patients with post-operative infection who had higher 10-year survival. This underlined the potential impact of immune system reactivation on the therapeutic response [Miwa *et al.*, 2019]. Immune infiltration is a common feature of bone sarcoma of bone sarcomas and includes T and B lymphocytes, NK cells, polynuclear cells and macrophages [Tellez-Gabriel *et al.*, 2019; Heymann *et al.*, 2019; Withers *et al.*, 2019; Majzner *et al.*, 2017; Palmerini *et al.*, 2017; Simard *et al.*, 2016; Inagaki *et al.* 2016]. This immune environment in sarcoma seems to play a crucial role in the tumor behavior however its functional evaluation and its value for predicting potential antitumoral response of immunotherapy are in the early stages of investigation [Kelleher and O'Sullivan, 2017; Palmerini *et al.*, 2017; Scott *et al.*, 2018]. Unfortunately, to date, most of clinical trials assessing immunotherapies in soft tissue and bone sarcomas have failed to induce an antitumoral response even if some positive responses have been observed [Tawbi *et al.*, 2017]. The recent disappointing clinical trials with some partial therapeutic response

demonstrate the necessity to: i) characterize the immune infiltrate in bone sarcoma; ii) understand its incapacity to lead to an efficient ant-tumor response; ii) determine the best strategy to re-induce an immunocompetent environment in bone sarcomas.

Targeting of tumor-associated macrophages in bone sarcomas

Macrophages and T-lymphocytes are the two main cell populations in the immune landscape of bone sarcomas [Majzner *et al.*, 2017]. Tumor-associated macrophages (TAMs) are very heterogeneous immune effectors, capable of tightly modulating the local immune response, and consequently the death/survival of tumor cells, as well as impacting tumor progression and the metastatic process by acting on angiogenesis (Figure 1B). The concept based on an anti-tumor response triggered by bacterial products such as endotoxins and activating the host's immune cells has been revised in the 1980's. A synthetic analog of a component of the bacterial cell wall (Liposome-encapsulated muramyl tripeptide phosphatidyl ethanolamine or [L-MTP-PE](#), commercialized as Mifamurtide) was produced and assessed in pre-clinical models and clinical trials [Mori *et al.*, 2008; Ando *et al.*, 2011]. Soluble L-MTP-PE binds to the [TLR4](#) receptors expressed at the cell membrane of mononuclear phagocytes and its internalized form is recognized by [Nod2](#) restricted to monocytes, macrophages, dendritic cells, and intestinal Paneth cells which is an intracellular sensor of muramyl dipeptide (MDP) a peptidyl glycan detected in the bacterial wall [Nardin *et al.*, 2006]. The interactions between L-MTP-PE and its receptors result in intracellular signal transduction pathways including NF κ B and the MAPK and the secretion of proinflammatory cytokines (e.g. [IL-1 \$\beta\$](#) , [IL-6](#), [TNF- \$\alpha\$](#) , chemokines) driving an inflammatory reaction, dendritic cell recruitment, polarization of T-helper lymphocyte and toxic effects on tumor cells [Ando *et al.*, 2011; Kager *et al.*, 2010; Mori *et al.*, 2008; Nardin *et al.*, 2006]. Independently of Nod2, [MDP](#) also triggers a molecular cascade that includes the activation of [NLRP3](#), the cleavage of procaspase-1 into active

[caspase-1](#) and the activation of proinflammatory cytokines [Marine-Garcia *et al.*, 2008]. L-MTP-PE was then assessed in monotherapy and in combination with chemotherapy [Kleinerman *et al.*, 1995; Meyer *et al.*, 2008]. The results issued from the phase III Intergroup-INT0133 trial published by Meyer *et al.* (2008) showed an improvement of overall survival from 70 to 78% (p=0.03) in non-metastatic osteosarcoma when L-MTP-PE was combined with chemotherapy and in a one-third reduction in the risk of death from osteosarcoma. A year after, the analysis of the metastatic cohort did not achieve a statistical improvement in outcome [Chou *et al.*, 2009]. To clarify the potential benefit of mifamurtide which has shown promising effects, a recent phase II clinical trial (Sarcome-13/OS2016, ClinicalTrials.gov, n° NCT03643133) has been recently set up and plans to evaluate the efficacy of mifamurtide as add-on treatment to post-operative chemotherapy compared to post-operative chemotherapy alone in first-line treatment in metastatic osteosarcoma at the time of diagnosis or localized osteosarcoma with poor histological response [Brad *et al.*, 2019].

As a mirror image of the initial T-lymphocyte classification, the literature has described two main subpopulations of polarized TAMs: M1 with anti-tumor activities and M2-with pro-tumor impact [Noy and Pollard, 2014]. In bone sarcoma, analysis of biological cohorts revealed that M2 macrophagic infiltrate was associated with disease progression in osteosarcoma [Buddingh *et al.*, 2011; Dumars *et al.*, 2016], Ewing sarcoma [Hesketh *et al.*, 2015] and chondrosarcoma [Simard *et al.*, 2016]. The total number of macrophages was associated with good survival, but with a bad prognosis and prevalence of a higher risk of development of lung metastases in patients with the M2 phenotype (a predominance of M2-TAMs compared to the M1 subtype) [Buddingh *et al.*, 2011; Dumars *et al.*, 2016]. In a cohort of osteosarcoma samples, Han *et al.* (2016) studied the correlation between CD163⁺ M2

subtype and [TIM3^{+/-}PD1^{+/-}](#) T-lymphocyte infiltrates. They observed that TIM-3⁺ PD-1⁺ T-lymphocytes infiltrating osteosarcoma tissue exhibited weak proliferation and cytokine responses and were correlated with [IL-10](#) and M2-TAM. In this context, TIM3⁺PD1⁺ T-lymphocytes may be considered as immune suppressive T cells in osteosarcoma, and they hypothesized the therapeutic benefit of depleted M2-TAMs which would increase T-cell proliferation and release of pro-inflammatory cytokines.

With relation to the functional negative impact of M2-TAMs on bone sarcoma development, drugs modulating macrophage polarization or targeting M2 macrophages are of major therapeutic interest. Among these drugs, L-MTP-PE in combination with [IFN \$\gamma\$](#) may inhibit osteosarcoma cell proliferation *in vitro* thanks to its effect on the polarization of M1-macrophages independently of their release of IL-1 β , TNF- α and [nitric oxid](#) [Pahl *et al.*, 2014]. In this context, IFN- γ may be interesting for optimizing L-MTP-PE activity in osteosarcoma patients. In addition to the M1 macrophage anti-tumor activity, these authors also reported that IL-10-polarized M2-like macrophages could show anti-tumor activity against various osteosarcoma cell lines in an antibody-dependent manner and opens new potential immunotherapeutic approaches in osteosarcoma. [Trabectedin](#) is an alkylating agent initially extracted from the sea squirt *Ecteinascidia turbinata* and studied for its anti-tumor activity. Trabectedin induces anti-tumor activities through direct effects on tumor cells and indirect function on the tumor microenvironment. Trabectedin induces single-strand and double-strand DNA breaks, leading to the activation of the DNA damage-response. Consequently, this molecule has cytotoxic effect on cancer cells by inducing a p53 independent cell cycle arrest and also is responsible of macrophage apoptosis [Allavena *et al.*, 2005]. In addition, non-cytotoxic concentrations selectively inhibited the secretion of pro-inflammatory cytokines (e.g. [CXCL8](#), IL-6) by tumor cells [Germano *et al.*, 2010]. More recently, it has been demonstrated that trabectedin

depleted selectively monocytes and TAM in pre-clinical model of and soft-tissue sarcoma patients [Germano *et al.*, 2013]. M1- and M-2 TAM were similarly affected and this depletion associated mitochondrial depolarization and release of cytochrome C in the cytosol. The selectivity of trabectedin for mononuclear phagocyte versus the other leukocytes could be due to the differential [TRAIL](#) signaling [Germano *et al.*, 2013]. Recently, Jones *et al.* described similar activities in pre-clinical model of prostate cancer [Jones *et al.*, 2019]. In this clinical context, trabectedin targeted [F4/80](#)⁺CD206⁺ M2-TAMs, which were reduced after *in vivo* exposure to trabectedin and associated with reduced skeletal prostate tumor size.

Because, trabectedin induced DNA inducing single- and double-strand-breaks which can lead to the activation of [PARP1](#), the combination between the combination trabectedin and PARP1 inhibitor has been assessed. In pre-clinical of bone and soft-tissue sarcoma models, trabectedin and PARP1 inhibitors induced a synergistic decrease of tumor development [Grignani *et al.*, 2017]. Unfortunately, in “TOMAS” study (ClinicalTrials.gov, n° NCT02398058), a phase 1b clinical trial, the combination of PARP1 inhibitors (Olaparib 100–300 mg twice a day from day 1 to 21) and trabectedin (0.675–1.3 mg/m² every 3 weeks i.v.) was assessed in patients with bone and soft-tissue sarcoma. This combination showed manageable toxicity levels and resulted in encouraging anti-tumor activity in some soft-tissue sarcoma subtypes unfortunately no objective or clinical response was observed in the 11 patients suffering from bone sarcomas enrolled [Grignani *et al.*, 2018]. Very recently, SARC037 (ClinicalTrials.gov, n° NCT04067115, sponsor: Sarcoma Alliance for Research through Collaboration) is a phase 1 study that aims to evaluate the safety of trabectedin (1 mg over 1 hour infusion) combined with [irinotecan](#) in Ewing sarcoma. This study planned to enroll 45 patients and did not start to recruit yet.

Complementary pre-clinical studies underlined the therapeutic benefit of trabectedin. In a patient-derived orthotopic xenograft nude-mouse model, Igarashi *et al.* (2017) and Higuchi *et al.* (2019) observed that trabectedin may be able to bypass drug resistance in osteosarcoma. In addition, trabectedin may reprogram the tumor immune environment, making effective use of checkpoint inhibitors possible [Ratti *et al.*, 2017]. Like Mifamurtide or trabectedin, all-trans retinoic acid inhibits *in vitro* and in *in vivo* murine model of osteosarcoma the M2 polarization of TAMs [Zhou *et al.*, 2017]. This activity was independent of conventional [STAT3](#), [STAT6](#) or C/EBP β signaling but was associated with the transcriptional regulation of more than 1,200 genes and more specifically by the inhibition of [IL-13](#) or [IL-4](#) induced M2 polarization. All-trans retinoic acid would prevent the development of lung metastases by downregulating IL13-induced secretion of [MMP12](#). Similarly, dihydroxycoumarins showed antitumor and antimetastatic effect in a murine osteosarcoma model [Kimura and Sumiyoshi, 2015]. The dual effects of these drugs combined a direct effect on cancer cells characterized by a G1 cell cycle phase blockade and an indirect effect by inhibiting the differentiation of M2 macrophages through the inhibition of IL-10, [MCP-1](#) (CCL2) and [TGF- \$\beta\$ 1](#) secretion [Kimura and Sumiyoshi, 2015]. [IL-34](#) is a twin cytokine of [M-CSF](#) sharing the M-CSF receptor and a common macrophage target. This cytokine was detected in osteosarcoma patients [Segaliny *et al.*, 2015]. Drug targeting IL-34 may also represent an interesting therapeutic strategy for preventing osteosarcoma growth/metastasis by inhibiting M2-TAM recruitment mediated by the syndecan-1 [Foucher *et al.*, 2013; Segaliny *et al.*, 2015]. The effect of IL-34 remains controversial and may be dependent of the oncological entities [Lin *et al.*, 2019]. Overall, the data available in the literature demonstrated local intra-tumoral T cell-specific immunosuppression amplified by M2-TAMs and pointed out the potential interest to target specific subset of macrophages or to modulate their polarization. However, as described above even if most of pre-clinical studies published described pre-clinical benefit of

macrophage targeting in bone sarcomas, clinical trials did not confirm any of these observations in term of overall survival. The high heterogeneity of bone sarcoma cells and immune status of sarcoma tumors accentuates the complexity of a specific targeting of immune cell populations which should be adapted to each patient. Patient stratification must be improved and a better identification/characterization of TAMs (e.g. pro- or anti-tumor subtypes) as well as their correlation with T cell populations (e.g. T cell-effectors, -modulators, expression of checkpoint molecules) are necessary. Further clinical investigations are then mandatory. In this context, “Micros” clinical trial (ClinicalTrials.gov, n°NCT03737435) is an observational study which aims to characterize the tumor microenvironment in patients with localized osteosarcoma treated with Mifamurtide. The investigators aim to correlate the level of the [PDL-1](#) checkpoint with event-free survival and overall-survival, and with M1 (anti-tumor macrophages) and M2 (pro-tumor macrophages) (Figure 1B).

Dendritic cells for improving the immune recognition of bone sarcoma cells

Dendritic cells are heterogeneous entities of antigen presenting cells that infiltrate tumor tissues and exhibit a critical function in the priming and maintenance of local immunity. Dendritic cells are dedicated to the antigen presentation to naïve T lymphocytes in order to stimulate their differentiation toward professional cancer cell killers and they can also activate $\gamma\delta$ T-lymphocytes with marked antitumour functions [Fiore *et al.*, 2000]. In order to escape to the immune surveillance, tumors most frequently endeavor to moderate the antigen presentation by antigen-presenting cells leading to a local immunosuppression and a defective immune response. Dendritic cell based therapies have been proposed to bypass this process and is designed as dendritic cell vaccines. Neoantigens are tumor-specific antigens not expressed by normal cells. They derive from random somatic mutations and can be

recognized by the immune system in contrast to non-mutated self-antigens. Unfortunately, the low clonal frequency of neoantigen-specific cytotoxic T lymphocytes and the inefficient presentation of tumor-associated antigens lead to the defective anti-tumor response. Based on this observation, cancer vaccine or adoptive T cell therapies have been proposed to potentiate the immune response against these tumor-associated antigens. Bone sarcomas expressed specific antigens (Table 1) which have stimulated the development of targeted therapies. Effective anti-cancer therapies alone or in combination have thus been designed in bone sarcomas to stimulate tumor-associated dendritic cell function as a means of driving the anti-tumor immune response and preclinical results showed promising results [Li *et al.*, 2019; He *et al.*, 2016; Fang *et al.*, 2015; Kawano *et al.*, 2015]. Clinical investigations did not confirm the results of pre-clinical studies. Indeed, Himoudi *et al.* (2012) assessed a vaccine therapy based on autologous DCs matured with autologous tumour lysate and keyhole limpet haemocyanin in 12 patients with relapsed osteosarcoma. Patients received 3 weekly vaccines up to 6 vaccinations. The dendritic cell immunotherapy was safe with no apparent toxicity however dendritic cell vaccine therapy was associated a significant anti-tumor response in only 2 out of 12 vaccinated patients with no evidence of clinical benefit. Krishnadas *et al.* (2015) used dendritic cells pulsed with overlapping peptides derived from full-length MAGE-A1, MAGE-A3 and NY-ESO-1 antigen tumors to treat relapsed/refractory solid tumors, including Ewing sarcoma and osteosarcoma (10 patients evaluable aged 2.5 to 15 years with relapsed disease). Four cycles consisted in autologous dendritic cells (10 mg/m²/day for 5 days week 1 and dendritic cell vaccine once weekly on weeks 2 and 3. The clinical benefit was limited and only one objective response (complete remission) was documented. In 2017, Miwa *et al.* published the results of a phase 1/2 clinical trial analyzing the therapeutic benefit of autologous dendritic cells pulsed with autologous tumor lysate 37 patients with advanced bone and soft tissue sarcomas. No severe adverse effect was observed and an interesting

immunological response was detectable as revealed with increased serum levels of IFN γ and [IL-12](#), 4 weeks after cell injection. However, only one patient showed a partial clinical response, 6 had stable disease and the tumor progressed in 28 patients. An adequate recognition of tumor cells by antigen-specific cytotoxic T lymphocytes is a prerequisite to obtain an efficient tumor response. In order to evade immune recognition, cancer cells tend to repress the expression of tumor-specific antigen and MHC complex molecules. Dendritic cells based immunotherapies did not allow significant clinical responses in relapsed disease even if immunological was detectable. Overall, the promising pre-clinical results lead to disappointing clinical data. The increased immunosuppressive cells associated to the tumor burden could be responsible of the absence of objective clinical response. In such context, it would be necessary to assess dendritic based immunotherapy in the prevention of the relapse disease (in patients without any detectable metastasis or detectable recurrent disease). Furthermore, substantial improvements of the preparation of dendritic cells are mandatory, more specifically to improve their maturation process and to optimize their capacity of tumor antigen presentation and the initiation of efficient immune response.

Tumor lymphocyte infiltrate in bone sarcomas

Bone sarcomas are also characterized by moderate lymphocyte infiltration (less than 10% of cells). In Ewing sarcoma, CD8⁺ TILs have been detected in tumor samples; however, they were not correlated with histological subtypes, tumor location, or programmed cell death (PD)-1 and PD-Ligand (L)-1 expression, nor with either progression-free survival or overall survival [Machado *et al.*, 2018]. Interestingly, PD-1 was expressed in 26% of tumor cells and may have prognostic and therapeutic implications. In chondrosarcoma, TILs were detectable and correlated with PDL-1 expression, being highly-expressed in dedifferentiated

chondrosarcomas. PDL-1 expression was also correlated with positive HLA class I expression, but not with overall survival [Kostine *et al.*, 2018].

In osteosarcoma, [CD4⁺](#) and CD8⁺ tumor infiltrating lymphocytes (TILs) were isolated from fresh patient samples and showed higher *ex vivo* cytotoxic activity than autologous circulating T cells [Théoleyre *et al.*, 2005; Koirala *et al.*, 2016]. In contrast to Ewing sarcoma and chondrosarcoma, the ratio between CD8⁺ T cells and regulatory T cells was informative in terms of overall survival, and a decreased ratio was associated with decreased survival, as shown in dogs [Biller *et al.*, 2010]. These data have been confirmed more recently in a cohort of human osteosarcoma patients and revealed that quantification of the CD8⁺/FOXP3⁺-ratio in biopsies prior to chemotherapy makes it possible to identify patients with better survival [Fritzsching *et al.*, 2015]. However, an increase in CD14⁺ macrophage infiltrates is associated with Cytotoxic T-Lymphocyte Associated Protein 4 positive ([CTLA-4⁺](#)) T cells and a systemic immunosuppression status, as shown by an increased number of peripheral CD14⁺HLA-DR^{low/neg} immunosuppressive monocytes [Hingorani *et al.*, 2015]. Thus, despite the presence of macrophage and T-lymphocyte infiltrates, local immunosuppressive signals result in a tolerant environment and disease progression. A phase 2 (ClinicalTrial.gov, n°NCT03449108, sponsor: M.D. Anderson Cancer Center, USA) is currently recruiting bone sarcoma patients to evaluate the efficacy of autologous tumor infiltrating lymphocytes LN-145 (LN-145). The estimated study completion date is end of 2021 (Table 2).

Recently, D'Angelo *et al.* (2018) reported the therapeutic benefit of autologous T cells expressing NY-ESO-1^{e259} in synovial sarcoma. Similar approach is currently under investigation in bone sarcomas (ClinicalTrial.gov nNCT03462316, Phase 1 “NY-ESO-1 specific T cell receptor (TCR) T cell in sarcoma”, sponsor: Sun Yat-sen University, China)

(Table 2). Patients HLA-A*0201+ and exhibiting an initial tumor biopsy with more than 25% of NY-ESO-1 positive tumor cells could be enrolled. $\gamma\delta$ T-lymphocytes represent 1–5% of total blood T-lymphocytes in peripheral blood. $\gamma9\delta2$ T-lymphocyte heterodimers of V $\delta2$ and V $\gamma9$ chains constitute around 50–95% of all blood $\gamma\delta$ T cell populations [Silva-Santos *et al.*, 2015]. V $\gamma9$ V $\delta2$ T-lymphocytes are specifically dedicated to the recognition of non-peptidic antigens including pyrophosphomonoesters and alkylamines from microbial metabolites or organic compounds such as nitrogen-containing bisphosphonates. From these observations, several preclinical studies have provided evidence of the therapeutic benefits of using $\gamma\delta$ T-lymphocyte-based adoptive therapies with promising results [Murano *et al.*, 2007; Li *et al.*, 2012; Liu *et al.*, 2015; Wang, *et al.*, 2018]. $\gamma\delta$ T-lymphocyte activation contributes to tumor cell recognition through the engagement of TCR and/or NK receptors, including NKG2D [Silva-Santos *et al.*, 2015]. The low expression of NKG2D may restrain the $\gamma\delta$ T-lymphocyte response against tumor cells. To improve the tumor response of $\gamma\delta$ T cells, Wang Z. *et al.* (2018) combined T cell therapies with [decitabine](#), which may enhance NKG2D expression by osteosarcoma cells and then subsequently stimulate the cytotoxicity depending on the NKG2D - NKG2D ligand axis. Pre-treatment with nitrogen bisphosphonates has also been proposed to activate $\gamma\delta$ T-lymphocytes thanks to [isopentenyl pyrophosphate](#) release, which is produced after the internalization of nitrogen bisphosphonates by peripheral blood mononuclear cells [Wang S. *et al.*, 2018; Li *et al.*, 2012]. Unfortunately, recent knowledge has revealed the deleterious activities of $\gamma\delta$ T cells, which may promote tumor progression by acting as T regulator cells and inducing local immunosuppression, by interfering with dendritic cells and inhibiting the PD1-PDL1 functional pathway [Fleming *et al.*, 2017]. In this context, other adoptive therapies have been proposed to modulate the immune response in bone sarcoma.

Natural killer (NK) cells are a subset of lymphocytes that belong to the innate immune system and play a crucial role in the immune response against tumor cells and virus-infected cells, independently of any prior sensitization to antigens for the target recognition. NK adoptive therapies have already been assessed in murine models of bone sarcomas [Fernandez *et al.*, 2017; Guma *et al.*, 2014]. By using a model of metastatic osteosarcoma, a combination of NK cell therapy and inhalation of [IL-2](#) showed promising results and improved the survival of mice suffering from lung metastases [Guma *et al.*, 2014]. Fernandez *et al.* (2015) demonstrated the beneficial effects of expanded activated NK cells *in vitro*, and in an *in vivo* murine osteosarcoma model that was associated with marked NKGD2-NKGD2L cytotoxicity of all cancer cell subtypes, including tumor-initiating cells (Figure 1C). NK cell-based clinical trials are currently in progress. The NKEXPSARC study “Pilot study of expanded, activated haploidentical natural killer cell infusions for sarcomas” (ClinicalTrials.gov N° NCT02409576; sponsor: National University Hospital, Singapore) plans to analyze NK cell infusion in Ewing sarcomas (Table 2). The patients enrolled will receive lymphodepleting chemotherapy with [cyclophosphamide](#) (1 day) followed by [fludarabine](#) (5 days), and each patient will receive IL-2 on alternate days starting 1 day before infusion of the NK cells for a total of 6 doses. NCT02890758 (sponsor: Case Comprehensive Cancer Center, USA) is a phase 1 trial analyzing universal donor NK cell therapy in combination with a new compound (ALT803) that improves the survival of NK cells. Ewing patients will be enrolled. The STIR phase 2 study (ClinicalTrials.gov n°NCT02100891; sponsor: Medical College of Wisconsin, USA) will study haploidentical transplant and donor NK cells for solid tumors. Twenty patients will receive a reduced-intensity conditioning regimen (6 days) consisting of fludarabine (150 mg/m²), cyclophosphamide (29 mg/kg), and 3 Gy total body irradiation, followed by HLA-haploidentical marrow from a family member on Day 0. On days 3 and 4, cyclophosphamide (50 mg/kg) will be infused for selective *in vivo* T cell depletion.

Additional post-grafting immune suppression will associate [mycophenolate mofetil](#) with either [tacrolimus](#) or [sirolimus](#). NK cells will be selected from non-mobilized peripheral blood mononuclear cells on day 6 and infused into patients on day 7. The last one (Title: “Haploidentical stem cell transplantation and NK cell therapy in patients with high-risk solid tumors”; ClinicalTrial.gov n°NCT01807468) is sponsored by the Samsung Medical Center (Republic of Korea) and will recruit 12 patients, including osteosarcoma and Ewing sarcoma patients, who will receive expanded NK cell infusions and low-dose IL-2 to enhance NK cell alloreactivity.

Genetically-modified T lymphocyte therapies

To bypass human leukocyte antigen restrictions, the concept of chimeric antigen receptor (CAR) engineered T-lymphocytes (CAR T-cells) has been developed. CAR T-cells consist of a fusion of specific antibody-derived single-chain variable fragments with the signaling domain of a T cell receptor. The fusion leads to the expression of a chimeric receptor capable of recognizing antigens and inducing conventional activation signals from TCR [DeRenzo and Gottschalk, *et al.*, 2016]. The main advantage of CAR T-cells compared to $\alpha\beta$ TCR T-lymphocytes is that CAR T-cells can induce tumor death in a non-MHC restricted manner and may overcome the low levels of tumor antigen expression by cancer cells [Ahmed *et al.*, 2009] (Figure 1C). Diverse CAR T-cells have been developed based on this concept: CAR T-targeting [B7-H3](#) [Majzner *et al.*, 2019], [IFGR-1](#) and [ROR1](#) [Huan5 *et al.*, 2019], [IL-11](#) [Huang *et al.*, 2012], Folate receptor [Lu *et al.*, 2019], NKG2D/[4-1BB](#)/CD3z domains [Fernandez *et al.*, 2017], and CD166/[4-1BB](#) [Wang *et al.*, 2019]. A phase 1/2 clinical trial was conducted by Ahmed *et al.* (2015) in which patients with recurrent/refractory osteosarcoma (n=16) and Ewing sarcoma (n=1) expressing [HER2](#) received escalating doses of CAR T-cells targeting HER2. Interestingly, HER2-CAR T-cells were detectable in circulating

blood for 6 weeks after infusion and in the two patients assessed, HER2-CAR T-cells were observed at the tumor site. No sign of evident toxicity has been reported. However, although 4 patients of 17 evaluable patients had stable disease after HER2-CAR T-cell infusion, no radiologic complete responses were observed [Ahmed *et al.*, 2015]. In this trial, the authors did not observe any HER2-CAR T cell expansion that may be explained by the lack of lymphodepletion before CAR T cell infusion. The ongoing clinical trial combined CAR T-cells and lymphodepletion (Table 2). Thus, four clinical trials are currently in progress. The VEGAS study “iC9-GD2-CAR-VZV-CTLs/refractory or metastatic GD2-positive sarcoma and neuroblastoma” (ClinicalTrial.gov N°NCT01953900, Sponsor: Baylor College of Medicine, USA) aims to determine the largest safe dose of GD2-CAR T- cells combined with a varicella zoster vaccine and lymphodepletion by chemotherapy. Similarly, the NCT02107963 phase I trial (Sponsor: National Cancer Institute, USA) has recently been completed and assessed escalating doses of GD2 CAR T cells after cyclophosphamide-based lymphodepletion in children and young adults with GD2⁺ solid tumors, including osteosarcoma. In an open-label, non-randomized phase 1 study sponsored by the Seattle Children’s Hospital (USA), CAR T-cells targeting [EGFR](#) and CD19 will be assessed, and 36 patients will be enrolled (ClinicalTrial.gov n°NCT03618381, “EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults”). Finally, the safety and efficacy of the 4th generation of CAR T cell (4SCAR-Ig T-cells) targeting cells surface sarcoma antigens was initiated in 2017 by the Shenzhen Geno-Immune Medical Institute (China) (ClinicalTrial.gov n°NCT03356782). CAR T-cells have not proven yet their efficacy in bone sarcomas. However, clinical trials are mandatory to improve our knowledge about CAR T-cells functions: 1) the capacity of CAR T-cells to infiltrate metastatic foci of bone sarcomas more specifically the lung micrometastases, ii) the potential impact of the local immunosuppressive microenvironment on CAR T-cells activities, iii) the functional

relationship between genes expressed at the metastatic sites and CAR T-cells migration and functions. Recently, Morrow *et al.* (2018) studied the contribution of enhancer elements to the metastatic phenotype of osteosarcoma. They identified specific regions named Metastatic Variant Enhancer Loci that drive coordinated waves of gene expression during metastatic colonization of the lung. Interestingly, the activity of these enhancers and their associated gene targets were specifically controlled and not randomly regulated. A better understanding of the relationship between epigenomic profiling of the metastatic microenvironment and infiltrating CAR T-cells would be possible by the full analysis of resection lesions and will allow to identify new potential therapeutic combinations (e.g. with immune checkpoint inhibitors).

Immune checkpoint blockade in bone sarcomas

Initial immunotherapy strategies aimed to restimulate the immune system, which was in a state of anergy. Cytokine therapies, such as inoculation/inhalation of IL-2, were proposed to activate cytotoxic T-lymphocytes with limited success in terms of survival [Mori *et al.*, 2006]. Recent identification of multiple co-inhibitory molecules controlling the communications between cancer cells and immune actors provided a new explanation for the “immune brake” observed in oncology, opening up a new therapeutic era specifically for keeping the immune brake off. These protagonists, called immune checkpoints, include stimulatory ([CD27](#), [CD28](#), etc.) and inhibitory (B7-H3, CTLA-4, etc.) checkpoint molecules [Schildberg *et al.*, 2016] (Figure 1A). Numerous recent publications have demonstrated the expression of immune checkpoints by bone sarcomas in order to escape immune surveillance. For example, osteosarcoma and chondrosarcoma express PDL-1/PDL-2 [Thanindratarn *et al.*, 2019; McEachron *et al.*, 2018; Yang *et al.*, 2018; Zheng *et al.*, 2018; Sandara *et al.*, 2017; van Erp *et al.*, 2017], B7-H3 [Yin *et al.*, 2015; Wang *et al.*, 2013], HHLA-2 [Koirala *et al.*, 2016]. B7-

H4 is expressed by osteosarcoma cells [Dong *et al.*, 2015]. Ewing sarcoma expresses the B7-H3 protein [Majzner *et al.*, 2019] but not PDL-1 [Spurny *et al.*, 2018]. Sandara *et al.* (2017) observed an increased number of TILs and PD-L1 expression in metastases compared to primary tumors and reinforced the therapeutic value of checkpoint inhibitors in patients with metastatic disease. In this context, the targeting PD-1/PDL-1 axis was assessed with success in preclinical models either alone [Shimizu *et al.*, 2018; Zheng *et al.*, 2018] or combined with irradiation [Xia *et al.*, 2018], CTLA-4 blocking antibodies [Lussier *et al.*, 2018], L-arginine [He *et al.*, 2017] or myeloid-derived suppressor cells [Guan *et al.*, 2018]. Interestingly, the PD-1 blockade increased the number of anti-tumor M1 macrophages and decreased the recruitment of pro-inflammatory M2 macrophages, resulting in regression of lung metastases in a murine model of osteosarcoma [Dhupkar *et al.*, 2017]. As described previously for other immunotherapeutic approaches, ant-PD1 and anti-PDL1 therapeutic approaches gave disappointing results. In SARC028 phase II clinical trials (ClinicalTrials.gov, n° NCT02301039), (2017) *et al.* assessed an anti-PD-1 antibody ([Pembrolizumab](#)) in patients suffering from soft –tissue or bone sarcoma. Forty bone sarcoma patients were enrolled and received 200 mg *i.v.* pembrolizumab every 3 weeks. Only 5% of patients had an objective response [one osteosarcoma (1/22), one chondrosarcoma (1/5) and none Ewing sarcoma (1/13)]. In the PEMBROSARC study (ClinicalTrials.gov, n° NCT02406781), Le Cesne *et al.* (2019) assessed the combination of pembrolizumab (200 mg *i.v.* every 3 weeks) with metronomic cyclophosphamide (50 mg *b.id.* one week on and one week off) in patients with advanced osteosarcomas. Partial response was observed in one patient (6.66%) of 15 enrolled, stable disease in 5 and progressive disease in 8. Immune infiltration was detected in all patients (14 patients) for who the data were available. CD3⁺ cells were observed as well as PDL-1 expression in tumor cells. Similarly, Paoluzzi *et al.* (2017) have retrospectively analyzed a small cohort of patients with relapsed sarcomas including 4 bone sarcomas treated

with an other anti-PD-1 antibody ([nivolumab](#), 3mg/kg *i.v.* every 2 weeks, median number of cycles: 8) and [pazopanib](#) (400–800 mg daily). The authors observed a partial response in one maxillary osteosarcoma. Clinical investigations of immune checkpoint inhibitors are at the early stage of knowledge in bone sarcoma and are generating considerable interest as shown by the ongoing clinical trials (Table 3).

Perspectives and Conclusions

Bone sarcomas are rare malignant entities characterized by rich and heterogeneous immune infiltrates which appear to be an asset for new immunotherapy programs ([Figure 2](#)). The dysregulation of macrophage recruitment in favor of anti-tumor M2 subsets, combined with regulatory T cell infiltrate, is responsible for an immune tolerant microenvironment which facilitates cancer cell survival, tumor growth and the metastatic process. Osteosarcoma and Ewing sarcoma are predominant in children and adolescent during bone growth. Bone remodeling is characterized by a permanent dialog between osteoblasts and osteoclasts and bone growth is marked by an increase of osteoclast number as well as osteoblastic activities. Osteoclast may play a important role in disease progression [Endo-Munoz *et al.*, 2012]. Indeed, a lost of osteoclast may facilitate the cancer cell migration to distant site, function that they do not have at the early stage of the disease. This dual activity could be explained by the high heterogeneity of osteoclasts composed by pro-inflammatory and immunocompetent osteoclast subsets [Madel *et al.*, 2019]. Bone cells and their functional impact in the immune system then define a unique tumor microenvironment for pediatric bone sarcomas. A better understanding and characterization of the tumour microenvironment which continuously evolve all along the disease history and the therapeutic lines with the selection is mandatory [Brown *et al.*, 2019].

The SARC028 clinical trial revealed interesting clinical responses in two adult sarcomas (undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma) in contrast to pediatric sarcoma (Ewing sarcoma and osteosarcoma) for which no objective response was observed [Tawbi *et al.*, 2017]. These results highlight a major difference between adult and pediatric cancers that may be explained by low expression of neoantigens in addition to their specific microenvironment [Chang *et al.*, 2017; Crompton *et al.*, 2014]. Indeed, genetic investigations have demonstrated the paucity of mutations more specifically involving targetable signal transduction pathways in pediatric sarcomas. This lack of targetable neoantigens reduces consequently the chance of success of immunotherapies. However, sarcomas are also characterized by high frequency of oncogenic fusion events responsible of the expression of fusion-derived neoantigens that represent alternative tumor-targets [Lorenz *et al.*, 2016; Anderson *et al.*, 2018]. Since sarcomas and most specifically pediatric sarcomas are characterized by a relatively low immunogenicity, any drug modulating the immune response, exacerbating the tumor antigen presentation would have its place in the therapeutic arsenal. PARP inhibitors are considered as immunotherapeutic sensitizers and may be one of these candidates [Césaire *et al.*, 2018].

The use of attenuated oncolytic viruses (e.g. herpes simplex virus, Maraba virus MG1, Seneca Calley virus, etc) inoculated directly into the tumor mass or delivered by macrophages have been proposed in oncology [Garcia-Moure *et al.*, 2016 ; Muthana *et al.*, 2013]. The main property of these viruses is their capacity to propagate preferentially in tumor environment that lacks innate defences. Oncolytic viruses then lead to a local inflammation and a secondary immune response similarly to a vaccine approach. Cripe *et al.* (2015) assessed an oncolytic and immunotherapeutic vaccinia virus in pediatric cancer. The formulation tested was safe and showed an objective biological activity in the Ewing sarcoma assessed, including necrotic changes in the injected tumor following the first injection. Combination

with conventional chemotherapy or modulator of the microenvironment was also envisaged [Martinez-Velez *et al.*, 2014 ; Denton *et al.*, 2018].

All drugs reprogramming the immune balance in tumor tissues thus represent a therapeutic option for improving overall survival in bone sarcomas. Most bone sarcoma cells express immune checkpoint proteins, contributing to their immune escape but that also opens up new therapeutic strategies. In this field, several clinical trials assessing checkpoint inhibitors that interrupt the repressive crosstalk between cancer and immune cells are currently in progress, either as the single agent or combined with conventional chemotherapy. However, the low immunogenicity of pediatric tumors will require others approaches to unlock immunotherapeutic response. Full molecular profiling of all bone sarcomas is mandatory for looking for new tumor associated antigens and establishing a list of immune checkpoint proteins expressed by cancer cells and their environment according to histological subtypes and grading. The 100,000 genomes project in progress in the UK is one example of the ambitious ongoing project. The list of targetable biomarkers is a crucial step for future clinical development by improving patient stratification. The anecdotal immunotherapeutic responses described in most of the clinical trials is an argument in favor a better identification of patients most likely to respond and then a better selection of patients enrolled.

REFERENCES

- Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., *et al.* (2015). Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. *J Clin Oncol.* 33(15),1688-96. doi: 10.1200/JCO.2014.58.0225.
- Ahmed, N., Salsman, V.S., Yvon, E., Louis, C.U., Perlaky, L., Wels, W.S., *et al.* (2009). Immunotherapy for osteosarcoma : genetic modification of T cells overcomes low levels of tumor antigen expression. *Mol Ther.* 17(10),1779-87. doi: 10.1038/mt.2009.133.
- Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F. *et al.* (2005). Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. *Cancer Res* 65(7):2964-2971. doi: 10.1158/0008-5472.CAN-04-4037
- Anderson, M.D., de Borja, R., Young, M.D., Fuligni, F., Rosic, A. Roberts, N.D. *et al.* (2018). Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. *Science* 361(6405). doi: 10.1126/science.aam8419.
- Ando, K., Mori M., Corradini, N., Redini, F., Heymann, D. (2011) Mifamurtide for the treatment of nonmetastatic osteosarcoma, *Expert Opin. Pharmacother.* 12 ;285-292. doi: 10.1517/14656566.2011.543129.
- Borowski, A., Dirksen, U., Lixin, L., Shi, R.L., Göbel, U., Schneider, E.M. (2006). Structure and function of ETAA16: a novel cell surface antigen in Ewing's tumours. *Cancer Immunol Immunother.* 55(4), 363-374. doi : 10.1007/s00262-005-0017-6
- Brard, C., Piperno-Neumann, S., Delaye, J., Brugières, L., Hampson, L.V. Le Teuff, G. *et al.* (2019). Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. *BMJ Open* 9(5),e025877. doi: 10.1136/bmjopen-2018-025877.
- Biller, B.J., Guth, A., Burton, J.H., Dow, S.W. (2010). Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. *J Vet Intern. Med.* 24 (2010) 1118-1123. doi: 10.1111/j.1939-1676.2010.0557
- Bluman EM, Coulie PG, Xiaojuan S, Machan J, Lin C, Meitner PA, *et al.* (2007). Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules. *J Orthop Res.* 25, 678-684. doi : 10.1002/jor.20368
- Brinkmann, U; Vasmatazis, G., Lee, B., Pastan, I. (1999). Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. *Cancer Res.* 59(7), 1445-1448. PMID: 10197611
- Brown, H.K., Schiavone, K., Gouin, F., Heymann, M.F., Heymann D. (2018). Biology of bone sarcomas and new therapeutic developments. *Calcif Tissue Int.* 20102(2),174-195. doi: 10.1007/s00223-017-0372-2.

Brown, H.K., Tellez-Gabriel, M., Cartron, P.F., Vallette, F.M., Heymann, M.F., Heymann, D. (2019). Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? *Drug Discov Today* 24(3),763-772. doi: 10.1016/j.drudis.2018.11.017

Buddingh, E.P., Kuijjer, M.L., Duim, R.A., Bürger, H., Agelopoulos, K., Myklebost, O., *et al.* (2011). Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. *Clin Cancer Res.* 17,2110-2119. doi: 10.1158/1078-0432.CCR-10-2047.

Burnet, F.M. (1970). The concept of immunological surveillance. *Prog Exp Tumor Res.* 13,1-27. PMID: 4921480

Césaire, M. Thariat, J., Candéias, S.M., Stefan, D., Saintigny, Y., Chevalier, F. (2018). Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer? *Int J Mol Sci.* 19(12). doi: 10.3390/ijms19123793.

Chang, T.C., Carter, R.A., Li, Y., Li, Y., Wang, H., Edmonson, M.N., *et al.* (2017). The neoepitope landscape in pediatric cancers. *Genome Med.* 9(1),78. doi: 10.1186/s13073-017-0468-3

Chou, A.J., Kleinerman, E.S., Krailo, M.D., *et al.* (2009). Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. *Cancer* 115,5339-48. doi: 10.1002/cncr.24566

Cripe, T.P., Ngo, M.C., Geller, J.I., Louis, C.U., Currier, M.A., Racadio, J.M., *et al.* (2015). Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. *Mol Ther.* 23(3),602-608. doi: 10.1038/mt.2014.243

Crompton, B.D., Stewart, C., Taylor-Weiner, A., Alexe, G., Kurek, K., *et al.* (2014). The genomic landscape of pediatric Ewing sarcoma. *Cancer Discov.* 4(11),1326-1341. doi: 10.1158/2159-8290.CD-13-1037

D'Angelo, S.P., Melchiori, L., Merchant, M.S., Bernstein, D., Glod, J., Kaplan, R. *et al.* (2018). Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 ⁶²⁵⁹T cells in synovial sarcoma. *Cancer Discov.* 8(8), 944-957. doi: 10.1158/2159-8290.CD-17-1417

D'Arcy, P., Maruwge, W., Wolahan, B., Ma, L., Brodin, B. (2014). Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells. *PLoS One.* 9(4),e95136. doi: 10.1371/journal.pone.0095136. eCollection 2014.

Denton, N.L., Chen, C.Y., Hutzen, B., Currier, M.A., Scott, T., Nartker, B., *et al.* (2018). Myelolytic treatments enhance oncolytic herpes virotherapy in models of Ewing sarcoma by modulating the immune microenvironment. *Mol Ther Oncolytics* 11,62-74. doi: 10.1016/j.omto.2018.10.001.

DeRenzo, C., Gottschalk, S. (2016). Genetically modified T-cell therapy for the treatment of

- osteosarcoma: an update. *J Clin Cell Immunol.* 7(2). doi: 10.4172/2155-9899.1000417
- Dong, Q., Ma, X. B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma. *Biomed Res Int.* 2015,156432. doi: 10.1155/2015/156432.
- Dhupkar, P., Gordon, N., Stewart, J., Kleinerman, E.S. (2018). Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. *Cancer Med.* 7(6),2654-2664. doi: 10.1002/cam4.1518.
- Dumars, C., Ngyuen, J.M., Gaultier, A., Lanel, R., Corradini, N., Gouin F., *et al.* (2016) Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. *Oncotarget* 7(48),78343-78354. doi: 10.18632/oncotarget.13055.
- Dunn, G.P., Old, L.J., Schreiber, R.D. (2004) The three Es of cancer immunoediting. *Annu Rev Immunol.* 22,329-60. doi: 10.1146/annurev.immunol.22.012703.104803
- Endo-Munoz, L., Evdokiou, A., Saunders, N.A. (2012). The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. *Biochim Biophys Acta* 1826(2),434-42. doi: 10.1016/j.bbcan.2012.07.003.
- Fang, X., Jiang, C., Xia, Q. (2015). Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response. *Genet Mol Res.* 14(4),11763-70. doi: 10.4238/2015.October.2.10.
- Fernández, L., Metais, J.Y., Escudero, A., Vela, M., Valentín, J., Vallcorba, I., *et al.* (2017). Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells. *Clin Cancer Res.* 23(19),5824-5835. doi: 10.1158/1078-0432.CCR-17-0075.
- Fernández, L., Valentín, J., Zalacain, M., Leung, W., Patiño-García, A., Pérez-Martínez, A. (2015). Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. *Cancer Lett.* 368(1),54-63. doi: 10.1016/j.canlet.2015.07.042.
- Fiore, F., Castella, B., Nuschak, B., Bertieri, R., Mariani, S., Bruno, B., *et al.* (2007). Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. *Blood* 110(3),921-927. doi : 10.1182/blood-2006-09-044321
- Fleming, C., Morissey, S., Cai, Y., Yan, J (2017). $\gamma\delta$ T Cells: Unexpected Regulators of Cancer Development and Progression. *Trends Cancer.* 3(8),561-570. doi: 10.1016/j.trecan.2017.06.003.
- Foell, J.L., Hesse, M., Volkmer, I., Schmiedel, B.J., Neumann, I., Staeger, M.S. (2008). Membrane-associated phospholipase A1 beta (LIPI) Is an Ewing tumour-associated cancer/testis antigen. *Pediatr Blood Cancer* 51(2),228-234. doi: 10.1002/pbc.21602.
- Foucher, E.D., Blanchard, S., Preisser, L., Garo, E., Ifrah, N., Guardiola, P., *et al.* (2013). IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages.

antagonistic effects of GM-CSF and IFN γ . PLoS One 8(2), e56045. doi: 10.1371/journal.pone.0056045.

Fritzsching, B., Fellenberg, J., Moskovszky, L., Sapi, Z., Krenacs, T., Machado, I., *et al.* (2015). CD8⁺/FOXP3⁺ ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicentre validated retrospective study. *Oncoimmunology* 4; e990800. DOI: 10.4161/2162402X.2014.990800

Garcia-Moure, M., Martinez-Velez, N., Patino-Garcıa, A., Alonso, M.M. (2016). Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope. *J Bone Oncol* 9,41-47. doi: 10.1016/j.jbo.2016.12.001

Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Psce, S. *et al.* (2010). Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. *Cancer Res* 70(6),2235-44. doi: 10.1158/0008-5472.CAN-09-2335.

Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., *et al.* (2013) Role of macrophage targeting in the antitumor activity of trabectedin. *Cancer Cell* 23(2),249-62. doi: 10.1016/j.ccr.2013.01.008.

Grignani, G., D'Ambrosio, L., Pignochino, Y. (2018). Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. *Lancet Oncol.* 19(10),1360-1371. doi: 10.1016/S1470-2045(18)30438-8.

Guan, Y., Zhang, R., Peng, Z., Dong, D., Wei, G., Wang, Y. (2017). Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer. *J Bone Oncol.* 9,59-64. doi: 10.1016/j.jbo.2017.10.002.

Guma, S.R., Lee, D.A., Ling, Y., Gordon, N., Kleinerman, E.S. (2014). Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. *Pediatr Blood Cancer.* 61(8),1362-8. doi: 10.1002/pbc.25019.

Han, Q., Shi, H., Liu, F. (2016). CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. *Int Immunopharmacol.* 34,101-106. doi: 10.1016/j.intimp.2016.01.023.

He, X., Lin, H., Yuan, L., Li, B. (2017). Combination therapy with L-arginine and α -PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice. *Cancer Biol Ther.* 18(2),94-100. doi: 10.1080/15384047.2016.1276136.

He, Y.T., Zhang, Q.M., Kou, Q.C., Tang, B. (2016). *In vitro* generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma. *Oncol Lett.* 12(2),1101-1106. DOI:10.3892/ol.2016.4714

- Heiner, J.P., Miraldi, F., Kallick, S., Makley, J., Neely, J., Smith-Mensah, W.H., *et al.* (1987). Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. *Cancer Res.* 47(20), 5377-5381. PMID: 3115567
- Hesketh, A.J., Maloney, C., Behr, C.A., Edleman, M.C., Glick, R.D., Al-Abed, Y. *et al.* (2015). The macrophage inhibitor CNI-1493 blocks metastasis in a mouse model of Ewing sarcoma through inhibition of extravasation. *PLoS One.* 10(12),e0145197. doi: 10.1371/journal.pone.0145197.
- Heymann, M.F., Brown, H.K., Heymann, D. (2016). Drugs in early clinical development for the treatment of osteosarcoma. *Expert Opin Investig Drugs.* 25(11),1265-1280. DOI: 10.1080/13543784.2016.1237503
- Heymann, M.F., Lézot, F., Heymann, D. (2019) The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. *Cell Immunol.* 343:103711. doi: 10.1016/j.cellimm.2017.10.011.
- Higashi, H, Ito, M., Fukaya, N., Yamagata, S., Yamagata, T. (1990). Two-dimensional mapping by the high-performance liquid chromatography of oligosaccharides released from glycosphingolipids by endoglycoceramidase. *Anal Biochem* 186(2), 355-362. doi : 10.1016/0003-2697(90)90094-p
- Higuchi, T., Miyake, K., Oshiro, H., Sugisawa, N., Yamamoto, N., Hayashi, K., *et al.* (2019). Trabectedin and irinotecan combination regresses a cisplatin-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model. *Biochem Biophys Res Commun.* 513(2):326-331. 10.1016/j.bbrc.2019.03.191.
- Hingorani, P., Maas, M.L., Gustafson, M.P., Dickman, P., Adams, R.H., Watanabe, M., *et al.* (2015). Increased CTLA-4⁺T cells and an increased ratio of monocytes with loss of class II (CD14⁺ HLA-DR^{lo/neg}) found in aggressive pediatric sarcoma patients. *J Immunother. Cancer* 3,35. doi: 10.1186/s40425-015-0082-0
- Himoudi, N., Wallace, R., Parsley, K.L., Gilmour, K., Barrie, A.U., Howe, K., *et al.* (2012). Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. *Clin Transl Oncol.* 14(4),271-279. doi: 10.1007/s12094-012-0795-1
- Huang, G., Yu, L., Cooper, L.J., Hollomon, M., Huls, H., Kleinerman, E.S. (2012). Genetically modified T cells targeting interleukin-11 receptor α -chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. *Cancer Res.* 72(1),271-81. doi: 10.1158/0008-5472.CAN-11-2778.
- Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E, Zhou, S.X., *et al.* (2015). IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas. *PLoS One.* 10(7), e0133152. doi: 10.1371/journal.pone.0133152.

Igarashi, K., Murakami, T., Kawaguchi, K., Kiyuna, T., Miyake, K., Zhang, Y., et al (2017). A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. *Oncotarget*. 8(37),62111-62119. doi: 10.18632/oncotarget.

Inagaki, Y., Hookway, E., Williams, K.A., Hassan, AB., Oppermann, U., Tanaka, Y., et al. (2016). Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumors. *Clin Sarcoma Res*. 6:13. doi: 10.1186/s13569-016-0053-3. eCollection 2016.

Jacobs, J. F. M., Brasseur, F., Hulsbergen-van de Kaa, C. A., van de Rakt, M.W., Figdor, C.G., Adema, G.J., *et al.* (2007). Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. *Int J Cancer* 120(1),67–74. doi: 10.1002/ijc.22118.

Jeys, L.M., Grimer, R.J., Carter, S.M., Tillman, R.M., Abudu, A. Post-operative infection and increased survival in osteosarcoma patients: are they associated ? (2007). *Ann Surg Oncol*. 14(10),2887-2895. DOI: 10.1245/s10434-007-9483-8

Jones, J.D., Sinder, B.P., Paige, D., Soki, F.N., Koh, A.J., Thiele, S., *et al.*(2019). Trabectedin reduces skeletal prostate cancer tumor size in association with effects on M2 macrophages and efferocytosis. *Neoplasia* 21(2),172-184. doi: 10.1016/j.neo.2018.11.003.

Kager, L., Pötschger, Bielack, S. (2010) Review of mifamurtide in the treatment of patients with osteosarcoma. *Ther Clin Risk Manag* 6,279-86. doi:10.2147/tcrm.s5688

Kailayangiri, S., Altvater, B., Meltzer, J., Pscherer, S., Luecke, A., Dierkes, C., *et al.* (2012). The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. *Br J Cancer* 106(6), 1123-1133. doi: 10.1038/bjc.2012.57.

Kawano, M., Tanaka, K., Itonaga, I., Iwasaki, T., Miyazaki, M., Ikeda, S., et al. (2015). Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma. *Oncol Rep*. 34(4),1995-2001. doi: 10.3892/or.2015.4161.

Kelleher, F.C., O’Sullivan, H. (2017). Monocytes, Macrophages, and Osteoclasts in Osteosarcoma. *J Adolesc Young Adult Oncol* 6(3), 396-405. doi: 10.1089/jayao.2016.0078.

Kimura, Y., Sumiyoshi, M. (2015). Antitumor and antimetastatic actions of dihydroycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G1 arrest in tumor cells. *Eur J Pharmacol*. 746,115-125. doi: 10.1016/j.ejphar.2014.10.048.

Kleinerman, E.S. Gano, J.B., Johnston, D.A., Benjamin, R.S., Jaffe, N. (1995). Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. *Am J Clin Oncol* 18(2):93-9. doi : 10.1097/00000421-199504000-00001

- Koirala, P., Roth, M.E., Gill, J., Piperdi, S., Chinai, J.M., Geller, D.S., *et al.* (2016). Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. *Sci Rep.* 6,30093. doi: 10.1038/srep30093.
- Kostine, M., Cleven, A.H., de Miranda, N.F., Italiano, A., Cleton-Jansen, A.M., Bovée, J.V. (2016). Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. *Mod Pathol.* 29(9),1028-37. doi: 10.1038/modpathol.2016.
- Krishnadas, D.K., Shusterman, S., Bai, F., Diller, L., Sullivan, J.E., Cheerva, A.C., *et al.* (2015). A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. *Cancer Immunol Immunother.* 64(10),1251-60. doi: 10.1007/s00262-015-1731-3.
- Kuldkepp, A., Karakai, M., Toomsoo, E., Reinsalu, O., Kurg, R. (2019). Cancer-testis antigens MAGEA proteins are incorporated into extracellular vesicles released by cells. *Oncotarget* 10(38),3694-3708. doi: 10.18632/oncotarget.26979.
- Lai, J.P., Robbins, P.F., Raffeld, M., Aung, P.P., Tsokos, M., Rosenberg, S.A., *et al.* (2012). NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. *Mod Pathol.* 25(6), 854-858. doi: 10.1038/modpathol.2012.31.
- Le Cesne, A., Marec-Berard, P., Blay, J.Y., Gaspar, N., Bertucci, F., Penel, N., *et al.* (2019) Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. *Eur J Cancer* 119, 151-157. doi: 10.1016/j.ejca.2019.07.018.
- Li, Y., Wang, D., Fang, X. (2019). In vitro generation of anti-osteosarcoma cytotoxic activity using dendritic cells loaded with heat shock protein 70-peptide complexes. *Fetal Pediatr Pathol.* 1-12. doi: 10.1080/15513815.2019.1600624.
- Li, Z., Peng, H., Xu, Q., Ye, Z. (2012). Sensitization of human osteosarcoma cells to Vg9d2 T cell mediated cytotoxicity by zoledronate. *J Orthop Res.* 30(5),824-30. doi: 10.1002/jor.21579
- Lin, C., Mak, S., Meitner, P.A., Wolf, J.M., Bluman, E.M., Block, J.A., *et al.* (2002). Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma. *Gene* 285(1-2), 269-78. doi: 10.1016/s0378-1119(02)00395-5
- Lin, W., Xu, D., Austin, C.D., Caplazi, P., Senger, K., Sun, Y., *et al.* (2019). Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer. *Front Immunol.* 2019 Sep 4;10:2019. doi: 10.3389/fimmu.2019.02019.
- Lipinski, M., Braham, K., Philip, I., Wiels, J., Philip, T., Goridis, C., *et al.* (1987). Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. *Cancer Res.* 47(1), 183-187. PMID: 3024814

- Liu, M., Sun, L.L., Li, Y.J., Li, H.Y., Zhang, J., Li, B.H., et al. (2015). Trastuzumab enhanced the cytotoxicity of V γ 9V δ 2 T cells against zoledronate-sensitized osteosarcoma cells. *Int Immunopharmacol.* 28(1),160-7. doi: 10.1016/j.intimp.2015.06.002.
- Lorenz, S., Barøy, T., Sun, J., Nome, T., Vodák, D., Bryne, J.C., Håkelien, A.M., et al. (2016). Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. *Oncotarget* 7(5), 5273-88. doi: 10.18632/oncotarget.6567
- Lu, Y.J., Chu, H., Wheeler, L.W., Nelson, M., Westrick, E., Matthaei, J.F., et al. (2019). Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies. *Front Oncol.* 9:151. doi: 10.3389/fonc.2019.00151.
- Lussier, D.M., Johnson, J.L., Hingorani, P., Blattman, J.N. (2015). Combination immunotherapy with α -CTLA-4 and α -PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. *J Immunother Cancer.* 3,21. doi: 10.1186/s40425-015-0067-z
- Machado, I., Lopez-Guerrero, J.A., Scotlandi, K., Picci, P., Llombart-Bosch, A. (2018). Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). *Virchows Arch.* 472(5),815-824. doi: 10.1007/s00428-018-2316-2.
- Madel, M.B., Ibáñez, L., Wakkach, A., de Vries, T.J., Teti, A., Apparailly, F., et al. (2019) Immune function and diversity of osteoclasts in normal and pathological conditions. *Front Immunol.* 2019 Jun 19;10:1408. doi: 10.3389/fimmu.2019.01408
- Marina-Garcia, N., Franchi, L., Kim, Y.G., Miller, D., McDonald, C., Boons, G.J., Nunez, G. (2008). Pannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2. *J Immunol* 180(6),4050-4057. doi: 10.4049/jimmunol.180.6.4050
- Majzner, R.G., Simon, J.S., Grosso, J.F., et al. (2017). Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. *Cancer* 123(19),3807-3815. doi: 10.1002/cncr.30724. Epub 2017 Jun 13.
- Majzner, R.G., Theruvath, J.L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C.W., et al. (2019). CAR T cells targeting B7-H3, a pan cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. *Clin Cancer Res.* 25(8),2560-2574. doi: 10.1158/1078-0432.CCR-18-0432.
- Martinez-Velez, N., Xipell, E., Jauregui, P., Zalacain, M., Marrodan, L., Zanduetta, C., et al. (2014). The oncolytic adenovirus Δ 24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity. *J Bone Miner Res.* 29(10),2287-2296. doi: 10.1002/jbmr.2253

- McEachron, T.A., Triche, T.J., Sorenson, L., Parham, D.M., Carpten, J.D. (2018). Profiling targetable immune checkpoints in osteosarcoma. *Oncoimmunology*. 7(12),e1475873. doi: 10.1080/2162402X.2018.1475873.
- Meyers, P.A., Schwartz, C.L., Krailo, M.D., *et al.* (2008). Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. *J Clin Oncol* 2008;26:633-638. doi: 10.1200/JCO.2008.14.0095.
- Miwa, S., Nishida, H., Tanzawa, Y., Takeuchi, A., Hayashi, K., *et al.* (2017). Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. *Cancer*. 123(9),1576-1584. doi: 10.1002/cncr.30606.
- Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi A., Igarashi K., *et al.* (2019). Current and emerging targets in immunotherapy for osteosarcoma. *J Oncol*. 2019:7035045. doi: 10.1155/2019/7035045.
- Mori, K., Ando, K., Heymann, D. (2008). Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, *Expert Rev Anticancer Ther*. 8,151-159. doi: 10.1586/14737140.8.2.151.
- Mori, K., Rédini, F., Gouin, F., Cherrier, B., Heymann, D. (2006). Osteosarcoma : current status of immunotherapy and future trends. *Oncol Rep*. 15(3),693-700. doi.org/10.3892/or.15.3.693
- Morrow, J.J., Bayles, I., Funnell, A.P.W., Miller, T.E., Saiakhova, A., Lizardo, M.M., *et al.* (2018). Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. *Nat Med*. 24(2),176-185. doi: 10.1038/nm.4475.
- Muraro, M, Mereuta, O.M., Carraro, F., Madon, E., Fagioli, F. (2007). Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. *Cell Immunol*. 249(2),63-72. doi: 10.1016/j.cellimm.2007.11.005.
- Muthana, M., Rodrigues, S., Chen, Y.Y., Welford, A., Hughes, R., Tazzyman, S., *et al.* (2013). Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. *Cancer Res*. 73(2),490-5. doi: 10.1158/0008-5472.CAN-12-3056
- Nardin, A., Lefbvre, M.L., Labroquère, K., Faure, O., Abastado, J.P. (2006). Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. *Curr Cancer Drug Targets* 6(2),123-33. DOI : 10.2174/156800906776056473
- Noy, R., Pollard, J.W. (2014). Tumor-associated macrophages: from mechanisms to therapy, *Immunity* 41, 49-61. doi: 10.1016/j.immuni.2014.06.010.
- Pahl, J.H., Kwappenberg, K.M., Varypataki, E.M., Santos, S.J., Kuijjer, M.L., Mohamed, S., *et al.* (2014). Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon- γ . *J Exp Clin Cancer Res*. 33,27. doi: 10.1186/1756-9966-33-27.

- Palmerini, E., Agostinelli, C., Picci, P., Pileri, S., Marafioti, T., Lollini, P.L., *et al.* (2017). Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. *Oncotarget* 8,111836-111846. doi: 10.18632/oncotarget.22912.
- Pignochino, Y., Capozzi, F., D'Ambrosio, L., Dell'Aglio, C., Basirico, M., Canta, M. *et al.* (2017). PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. *Mol Cancer* 16(1),86. doi: 10.1186/s12943-017-0652-5.
- Pollack, S.M., Li, Y., Blaisdell, M.J., Farrar, E.A., Chou, J., Hoch, B.L., *et al.* (2012). NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycytidine. *PLoS One* 7(2), e32165. doi: 10.1371/journal.pone.0032165.
- Polychronidou, G., Karavasilis, V., Pollack, S.M., Huang, P.H., Lee, A., Jones, R.L. (2017). Novel therapeutic approaches in chondrosarcoma. *Future Oncol.* 13(7),637-648. doi: 10.2217/fon-2016-0226.
- Ratti, C., Botti, L., Cancila, V., Galvan, S., Torselli, I., Garofalo, C., *et al.* (2017) Trabectedin overrides osteosarcoma differentiative block and reprograms the tumor immune environment enabling effective combination with immune checkpoint inhibitors. *Clin Cancer Res.* 23(17),5149-5161. doi: 10.1158/1078-0432.
- Scott, M.C., Temiz, N.A., Sarver, A.E., LaRue, R.S., Rathe, S.K., Varshney, J., *et al.* (2018). Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma. *Cancer Res.* 78(2),326-337. doi: 10.1158/0008-5472.CAN-17-0576.
- Schildberg, F.A., Klein, S.R., Freeman, G.J., Sharpe, A.H. (2016). Coinhibitory pathways in the B7-CD28 ligand-receptor family. *Immunity.* 44(5),955-72. doi: 10.1016/j.immuni.2016.05.002.
- Ségaly, A.I., Mohamadi, A., Dizier, B., Lokajczyk, A., Brion, R., Lanel, R., *et al.* Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. *Int J Cancer* 137,73-85. doi: 10.1002/ijc.29376.
- Shimizu, T., Fuchimoto, Y., Okita, H., Fukuda, K., Kitagawa, Y., Ueno, S., *et al.* (2018). A curative treatment strategy using tumor debulking surgery combined with immune checkpoint inhibitors for advanced pediatric solid tumors: An in vivo study using a murine model of osteosarcoma. *J Pediatr Surg.* 53(12),2460-2464. doi: 10.1016/j.jpedsurg.2018.08.023
- Silva-Santos, B., Serre K., Norell, H. (2015). $\gamma\delta$ T cells in cancer. *Nat Rev Immunol.* 15(11),683-91. doi: 10.1038/nri3904.

Simard, F.A., Richert, I., Vandermoeten. A., Decouvelaere, A.V., Michot J.P., Caux, C., *et al.* (2016) Description of the immune microenvironment of chondrosarcoma and contribution to progression. *Oncoimmunology*. 6(2),e1265716. doi: 10.1080/2162402X.2016.1265716.

Spurny, C., Kailayangiri, S., Jamitzky, S., Altvater, B., Wardelmann, E., Dirksen, U., *et al.* (2018). Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. *Pediatr Blood Cancer*. 65(1). doi: 10.1002/pbc.26719

Sundara, Y.T., Kostine, M., Cleven, A.H., Bovée, J.V., Schilham, M.W., Cleton-Jansen, A.M. (2017). Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. *Cancer Immunol Immunother*. 66(1):119-128. doi: 10.1007/s00262-016-1925-3.

Tan, P., Zou, C., Yong, B., Han, J., Zhang, L., Su, Q., *et al.* (2012). Expression and prognostic relevance of PRAME in primary osteosarcoma. *Biochem Biophys Res Commun*. 419(4),801-808. doi: 10.1016/j.bbrc.2012.02.110.

Tellez-Gabriel, M., Heymann, M.F., Heymann, D. (2019). Circulating tumor cells as a tool for assessing tumor heterogeneity. *Theranostics* 9(16),4580-4594. doi: 10.7150/thno.34337.

Thanindratarn, P., Dean, D.C., Nelson, S.D., Hornicek, F.J., Duan, Z. (2019). Advances in immune checkpoint inhibitors for bone sarcoma therapy. *J Bone Oncol*. 15,100221. doi: 10.1016/j.jbo.2019.100221.

Théoleyre, S., Mori, K., Cherrier, B., Passuti, N., Gouin, F., Rédini F., *et al.* (2005). Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. *BMC Cancer*. 5:123. DOI: 10.1186/1471-2407-5-123`

Tsuda, N., Murayama, K., Ishida, H., Matsunaga, K., Komiya, S., Itoh, K., *et al.* (2001). Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. *J Orthop Res*. 19(3),346-351. doi : 10.1016/S0736-0266(00)90031-7

Twabi, H.A., Burgess, M., Bolejack, V., Van Tine, B.A., Schuetze, S.M., Hu, J., D'Angelo, S., *et al.* (2017). Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol*. 18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1.

van Erp, A.E.M., Versleijen-Jonkers, Y.M.H., Hillebrandt-Roeffen, M.H.S., van Houdt, L., Gorris, M.A.J., van Dam, L.S., *et al.* (2017). Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8⁺ lymphocytes in primary sarcomas is subtype dependent. *Oncotarget*. 2017 Jul 7;8(41):71371-71384. doi: 10.18632/oncotarget.19071.

Wang, S., Li, H., Ye, C., Lin, P., Li, B., Zhang, W., *et al.* (2018). Valproic acid combined with zoledronate enhance $\gamma\delta$ T cell-mediated cytotoxicity against osteosarcoma cells *via* the

accumulation of mevalonate pathway intermediates. *Front Immunol.* 9 ,377.

Wang, L., Zhang, Q., Chen, W., Shan, B., Ding, Y., Zhang, G., et al. (2013). B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. *PLoS One.* 8(8,e70689). doi: 10.1371/journal.pone.0070689.

Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., et al. (2019). Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. *J Exp Clin Cancer Res.* 38(1),168.

Wang, Z., Wang, Z., Li, S., Li, B., Sun, L., Li, H., Lin, P., Wang, S. et al. (2018). Decitabine Enhances V γ 9V δ 2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells *via* the NKG2DL-NKG2D Axis. *Front Immunol.* 9,1239

Whelan, J.S., Davis, L.E. (2018) Osteosarcoma, Chondrosarcoma, and Chordoma. *J Clin Oncol* 10;36(2):188-193. doi: 10.1200/JCO.2017.75.1743.

Withers, S.S., York, D., Choi, J.W., Woolard, K.D., Laufer-Amorim, R., Sparger, E.E., et al. (2019). Metastatic immune infiltrates correlate with those of the primary tumor in canine osteosarcoma. *Vet Comp Oncol.* 17(3),242-252. doi: 10.1111/vco.12459.

Xia, L., Wu, H., Qian, W. (2018). Irradiation enhanced the effects of PD-1 blockade in brain metastatic osteosarcoma. *J Bone Oncol.* 12,61-64. doi: 10.1016/j.jbo.2018.05.002.

Yang, X., Zhu, G., Yang, Z., Zeng, K., Liu, F., Sun, J. (2018). Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma. *Int J Biol Markers.* 1724600818774464. doi: 10.1177/1724600818774464.

Yin, S.J., Wang, W.J., Zhang, J.Y. (2015). Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice. *Genet Mol Res.* 14(4),14253-61. doi: 10.4238/2015.

Zendman, A.J., Van Kraats, A.A., Weidle, U.H., Ruiter, D.J., Van Muijen, G.N. (2002). The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma. *Int J Cancer.* 99(3), 361-369. doi : 10.1002/ijc.10371

Zheng, B., Ren, T., Huang, Y., Sun, K., Wang, S., Bao, X., et al. (2018). PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. *Hematol Oncol.* 11(1),16. doi: 10.1186/s13045-018-0560-1.

Zheng, B., Ren, T., Huang, Y., Sun, K., Wang, S., Bao, X., et al. (2018). PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. *J Hematol Oncol.* 11(1),16. doi: 10.1186/s13045-018-0560-1.

Zhou, Q., Xian, M., Xiang, S., Xiang, D., Shao, X., Wang, J., et al. (2017). All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages. *Cancer Immunol Res.* 5,547-559. doi: 10.1158/2326-6066.CIR-16-0259.

Zou, C., Shen, J., Tang, Q., Yang, Z., Yin, J., Li, Z., *et al.* (2012). Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. *Cancer* 118(7),1845-1855. doi: 10.1002/cncr.26486.

Table 1 : Tumor associated antigens expressed by bone sarcoma cells

Tumor associated antigens	Osteosarcoma	Ewing sarcoma	Chondrosarcoma	References
CSAGE			+	Lin <i>et al.</i> , 2002 ; Zhou <i>et al.</i> , 2012
ETAA16		+		Borowski <i>et al.</i> , 2006
Gangliosides	+	+	+	Lipinski <i>et al.</i> , 1987 ; Heiner <i>et al.</i> , 1987 ; Kailyangiri <i>et al.</i> , 2012
LAGE	+	+	+	Pollack <i>et al.</i> , 2012
LIPI-1				Foell <i>et al.</i> , 2008
MAGE	+	-	+	Jacobs <i>et al.</i> , 2007 ; Kulkepp <i>et al.</i> , 2019; Pollack <i>et al.</i> , 2012, Bluman <i>et al.</i> , 2007; Zhou <i>et al.</i> , 2012
PRAME	+			Tan <i>et al.</i> , 2012
NY-ESO-1	+	-	+	Jacobs <i>et al.</i> , 2007 ; Lay <i>et al.</i> , 2012
SART-3	+	+	+	Tsuda <i>et al.</i> , 2001
SSX	+			D'Arcy <i>et al.</i> , 2014
XAGE		+		Brinkmann <i>et al.</i> , 1999; Zendman <i>et al.</i> , 2002

Table 2 : Cell immunotherapies in bone sarcomas : ongoing clinical trials

Immune cells	Phase	Sponsor	Title	Treatment regimen	Patient number	Bone sarcomas included	NCT reference	Status (October 2019)
Autologous tumor infiltrating lymphocytes	2	M.D. Anderson Cancer Center (USA)	LN-145 in treating patients with relapsed or refractory ovarian cancer, osteosarcoma, or other bone and soft tissue sarcomas	-Cyclophosphamide intravenously iv over 2 hours on days -7 and -6 - fludarabine phosphate iv over 30 minutes daily on days -5 to -1 -Autologous tumor infiltrating lymphocytes LN-145 iv over 45 minutes and aldesleukin iv over 30 minutes on days 1-4 for up to 6 doses.	80	*OS CS EWS	03449108	Recruiting
NY-ESO-1 TCR specific T cells prepared by lentiviral infection	1	Sun Yat-sen University (China)	NY-ESO-1-specific T cell receptor (TCR) T cell in sarcoma	- Seven days before TCR-T cell reinfusion, cyclophosphamide (15mg/kg/d x 3 days) + low-dose fludarabine (15mg/m2/d x 3 days) lymphocyte clearance. - Four days later, TCR-T cells (1×10^9 - 5×10^{10}) + IL-2 subcutaneous injections (250,000 IU/twice/day) within 15-30 minutes after cell reinfusion. - Possibility to increase cyclophosphamide (20 mg/kg/d x 3 days) and fludarabine (25 mg/m2/d x 3 days) for the follow-up	20	OS CS EWS	03676985	Recruiting
Natural Killer cells	1	National University Hospital, Singapore	Pilot study of expanded , activated haploidentical Natural Killer cell infusions for	Immunosuppressive chemotherapy before infusion of NK cells (Day -7 cyclophosphamide at 60mg/kg Day -6 fludarabine	20	EWS	02409576	Recruiting

			sarcomas (NKEXPSARC)	at 25mg/m ² daily for 5 days) - Radiation Each patient will receive radiation within 48 hr of NK cell infusion - IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses				
Natural Killer cells + ATL803 (IL-15 superagonist)	1	Case Comprehensive Cancer Center (USA)	Phase I trial of universal donor NK cell therapy in combination with ALT803	- Dose escalation of Natural Killer (NK) Cells from two infusion of 10 x 10 ⁶ cells/kg to 1000 x 10 ⁶ - ATL803 : 6mg/kg weekly for four weeks	54	EWS	02890758	Recruiting
Natural Killer cells	2	Samsung Medical Center, South Korea	Haploidentical stem cell transplantation and NK cell therapy in patients with high-risk solid tumors	-	12	OS EWS	01807468	Not yet recruiting
iC9-GD2-CAR-VZV-Cytotoxic T lymphocytes	2	Baylor College of Medicine (USA)	iC9-GD2-CAR-VZV-CTLs/refractory or metastatic GD2-positive sarcoma and neuroblastoma (VEGAS)	-Pre-infusion lymphodepletion: fudarabine and cyclophosphamide - One injection of GD2 T cells followed by VZV vaccine injection 42 days later. From 1 x 10 ⁶ cells/m ² to 1 x 10 ⁹ cells/m ²	26	OS	01953900	Recruiting
Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt	1	Seattle Children's Hospital (USA)	EGFR806 CAR T Cell immunotherapy for recurrent /refractory solid tumors in children and young adults	-	36	OS, EWS,	03618381	Recruiting
4th Generation of	1/2	Shenzhen	Safety and efficacy	- One CAR T-cell infusion,	20	OS	03356782	Recruiting

CAR T-cells 4SCAR-IgT cells		Geno-Immune Medical Institute (China)	evaluation of 4th generation safety- engineered CAR T cells targeting sarcomas	from 1×10^6 to 1×10^7 cells/kg		EWS		
--------------------------------	--	---	--	--	--	-----	--	--

*OS : osteosarcoma ; CS : chondrosarcoma ; EWS : Ewing sarcoma

Table 3 : Ongoing clinical trials in bone sarcomas based on inhibition of immune checkpoints

Drug	Phase	Sponsor	Title	Drug regimen	Patient number	Bone sarcomas included	NCT reference	Status (October 2019)
Avelumab (anti-PDL-1)	2	St. Jude Children's Research Hospital (USA)	A phase II trial of avelumab, a fully human antibody that targets Cells expressing PD-L1, in patients with recurrent or progressive osteosarcoma	Avelumab :10mg/kg i.v. over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. and avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.	40	OS	03006848	Recruiting
ZKAB001 (anti-PD-L1)	1/2	Lee's Pharmaceutical Limited (China)	A clinical study of PD-L1 antibody ZKAB001(Drug code) in limited stage of high-grade osteosarcoma	ZKAB001: 5, 10 or 15 mg/kg/times bi-weekly iv	9-18	OS	03676985	Recruiting
SHR-1210 (anti-PD-1)	2	Peking University People's Hospital (China)	Apatinib plus anti-PD1 therapy for advanced osteosarcoma	Apatinib 500mg or 250mg orally daily and SHR-1210 3 mg/kg (no more than 200mg) iv every 2 weeks	43	OS	03359018	Active, not recruiting
Pembrolizumab (anti-PD1)	2	Sarcoma Alliance for Research through Collaboration (USA)	SARC028: A phase II study of the anti-PD1 antibody pembrolizumab (MK-3475) in patients with advanced sarcomas	Pembrolizumab 200mg i.v. every 3 weeks	146	OS CS EWS	02301039	Active, not recruiting
	2	Oslo University Hospital (Norway)	PROMO: a study of pembrolizumab in patients with relapsed or metastatic osteosarcoma not eligible for	Pembrolizumab 200mg i.v. every 3 weeks for up to 35 cycles	12	OS	03013127	Active, not recruiting

			curative surgery					
Nivolumab (anti-PD1) +/- Ipilimumab (anti-CTL4)	1/2	National Cancer Institute (USA)	Nivolumab with or without ipilimumab in treating younger patients with recurrent or refractory solid tumors or sarcomas	Nivolumab 240mg i.v. every 2 weeks plus Ipilimumab 1 mg/m ² i.v. every 6 weeks	484	OS	02304458	Recruiting
Nivolumab + Ipilimumab	2	Assaf-Harofeh Medical Center (Israel)	A phase II of nivolumab plus ipilimumab in non-resectable sarcoma and endometrial carcinoma	Nivolumab 240mg i.v. every 2 weeks plus Ipilimumab 1mg/m ² i.v. every 6 weeks	60	CS EWS*	02982486	Not yet recruiting
Nivolumab + ABI-009 (Nab-rapamycin)	1/2	Sarcoma Oncology Research Center, LLC (USA)	Nivolumab (Opdivo®) plus ABI-009 (Nab-rapamycin) for advanced sarcoma	Nivolumab : 3 mg/kg, IV over 30 minutes q 3 weeks Nab-Rapamycin : iv over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in cycle 1. At Dose level 1, 56 mg/m ² ; Dose level 2, 75 mg/m ² ; Dose level 3, 100 mg/m ²	40	OS, EWS, CS	03190174	Recruiting
Nivolumab and Nivolumab + azacitidine	1/2	H. Lee Moffitt Cancer Center and Research Institute (USA)	Nivolumab or nivolumab and azacitidine in patients with recurrent, resectable osteosarcoma	Nivolumab : iv, 3 mg/kg on day 1 and 15 of each cycle. Azacitidine : Dose level 1, NA. Dose level 2, 60 mg/m ² . Dose level 3, 75 mg/m ²	51	OS	03628209	Recruiting
MASCT-I + PD1 antibody + Apatinib	1	SYZ Cell Therapy Co. (China)	Multiple Target Antigen Stimulating Cell Therapy (MASCT-I) combined with PD1	-	20	OS	04074564	Recruiting

			and apatinib in the treatment of tissue sarcoma					
Toripalimab (anti-PD-1)	1	Shanghai Junshi Bioscience Co., Ltd. (China)	Safety, tolerability and pharmacokinetics of an anti-PD-1 monoclonal antibody in subjects with advanced malignancies	-	258	CS	03474640	Recruiting

OS : osteosarcoma ; CS : chondrosarcoma ; EWS : Ewing sarcoma : * Metastatic Ewing sarcoma

Figure Legends

Figure 1: Immune infiltrates in bone sarcomas. Bone sarcoma tissues are invaded by numerous immune cells resulting in a permissive environment facilitating tumor progression and metastasis. **A)** Main molecular protagonists involved in the dialog between cancer or antigen presenting cells and T lymphocytes. The final effect on T cell effectors is a balance between activation (+) and repression signals. **B)** Macrophage infiltrate is composed by two main subsets: M1 macrophages with pro-tumor activities and M2 with anti-tumor activities. M2 subset is predominant with high bone sarcoma and is associated with the metastatic process. Cell-cell communications. **C)** Cancer cells can communicate with NK cells thanks the expression of NKG2L. The expression of a relative specific ligand by cancer is the origin of development of specific engineered CAR T cells recognizing cancer cells in a MHC independent manner.

Figure 2: Main immunotherapeutic approaches proposed for bone sarcomas. Tumour cells develop specific strategies to bypass the immune system. In this context, the two main therapeutic approaches are based on: i) the targeting of pro-tumoral effectors including M2 macrophages and the molecules associated with immune checkpoints; ii) the stimulation of anti-tumoral effectors. N-BPs: nitrogen containing bisphosphonates, DC: dendritic cells; NK: natural killer cells.



